Evaluation of the effect of metformin in STEMI patients treated with thrombolytic therapy
Phase 2
- Conditions
- Ischemic heart diseases patients.ischemic heart diseasesI20, I21,
- Registration Number
- IRCT20111206008307N34
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Ischemic heart diseases
age 18-80
undergoing of thrombolytic therapy
filling of consent form
Exclusion Criteria
Elevation of troponin I- (above normal) at least 48 hours before thrombolytic therapy
history of CABG during last three months
history of previous MI; renal failure (creatinine clearance below 30 mg / dl or creatinine above 1 /4 in women and 1/5 in men)
sensitivity to aspirin or clopidogrel and retaplase
cardiogenic shock; history of end-stage renal failure or dialysis
presence of metformin inhibition
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CTnI level. Timepoint: BASELINE?8?16? 24 AND 32 HOURS AFTER Thrombolytic. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method